Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhether a Mounjaro dose increase is right for you is a clinical decision, not a personal one you should make alone. Most people do move through the dose schedule over time, but the timing depends on how your body is responding, not on hitting a fixed number of weeks. These are prescription-only medicines, and every dose change needs a prescriber's sign-off. Here's what the evidence says about when — and why — titration happens.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common misunderstanding our prescribers hear. The belief goes: more medicine equals more effect, so if the scales aren't moving fast enough, the next dose up must be the answer. In practice, it's more complicated than that.
Mounjaro's titration schedule exists primarily to manage tolerability, not to dial up results week by week. The 2.5mg pen that starts treatment is there to settle your system, nausea, indigestion and fatigue are significantly more common when the dose climbs too fast. Moving up before your body has adapted tends to make side effects worse without meaningfully improving outcomes.
Weight loss on tirzepatide also doesn't always track the dose in a straight line. Many people notice a plateau for a few weeks, then further change. Eating patterns, sleep, stress and activity all interact with how the medicine works. If you're several weeks into a dose and feeling well-tolerated but discouraged by slower progress, that's worth discussing with your prescriber, not a reason to self-escalate. You can read more about why hunger sometimes persists in the early weeks, which often surprises people who expected immediate appetite change.
There are situations where moving to the next strength is clinically appropriate, and your prescriber will consider a few things together.
First, tolerability at the current dose. If you've been on a given strength for at least four weeks and side effects have settled to a manageable level, you're in the window where titration makes sense. The timing of when to increase a Mounjaro dose is typically guided by four-week steps, though some people stay longer at a particular strength if they're still experiencing GI symptoms.
Second, response over time. NICE's appraisal of tirzepatide notes that if someone hasn't achieved at least 5% weight loss after six months at the highest dose they can tolerate, continuing treatment is reviewed rather than automatically continued. That's a long horizon, it's not a reason to rush titration early, but it does mean the direction of travel matters. The full Mounjaro overview covers the licensed weight-management evidence in more detail.
Third, the specific dose you're on. The 5mg dose, for instance, is both a titration step and the first dose that many people consider genuinely therapeutic, what to expect at 5mg is a question worth understanding before assuming you need more.
If you're asking whether you need to increase your Mounjaro dose because you're feeling unwell on your current one, the answer is almost certainly: not yet. Persistent nausea, vomiting, or diarrhoea that hasn't eased within two weeks of a dose change is a signal to stay where you are or talk to your prescriber about whether a step back is right. Some people find a lower dose actually produces better long-term outcomes because they can stick with it.
For side effects specifically tied to the starting strength, the side effects at 2.5mg are worth understanding separately, this dose affects people differently from higher ones.
The NHS patient information for tirzepatide describes the full side-effect profile and which symptoms warrant urgent medical attention, including the NHS tirzepatide page. Severe stomach pain that spreads to the back, with or without vomiting, should be assessed urgently, this can be a sign of pancreatitis, which the MHRA highlighted in a 2026 safety communication for GLP-1 medicines.
At a GPhC-registered pharmacy like ours, a named prescriber) not an automated system, reviews your progress before authorising a dose change. That applies to every repeat, not just the first one. If you're transferring from another provider or requesting a higher strength, evidence of your current treatment and recent weight is required. That might feel like extra steps, but it's what clinical governance looks like in practice.
It's worth knowing that higher doses cost more per pen, and the difference between a 2.5mg and 12.5mg pen can be significant. Understanding Mounjaro's cost structure in the UK is genuinely useful context, especially if you're planning several months of treatment. One transparent price at each dose level, no subscription, no hidden fees, that's how it should work. Find out about the weight-loss treatments available through a regulated service if you're still weighing your options.
There's an honest question underneath all of this: whether increasing your Mounjaro dose is the right move depends entirely on your individual picture, which is exactly what a prescriber conversation is for. Nobody knows your response to treatment better than the clinician who has followed your progress. That conversation is also the right place to ask about why dose increases are built into the treatment model in the first place.
If you're unsure where you stand, speak to our prescribers, a free consultation is the starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.